Type 2 transglutaminase in Huntington’s disease: a double‐edged sword with clinical potential
Open Access
- 31 August 2010
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 268 (5) , 419-431
Abstract
Abstract. Mastroberardino PG, Piacentini M (Erasmus MC, Rotterdam, The Netherlands; University of Pittsburgh, Pittsburgh, PA, USA; University of Rome ‘Tor Vergata’, and National Institute for Infectious Diseases IRCCS ‘Lazzaro Spallanzani’, Rome, Italy) Type 2 transglutaminase in Huntington’s disease: a double‐edged sword with clinical potential (Review‐Symposium).J Intern Med2010;268: 419–431.Huntington’s disease (HD) is a dominant genetic neurodegenerative disorder. The pathology affects principally neurons in the basal ganglia circuits and terminates invariably in death. There is compelling necessity for safe and effective therapeutic strategies to arrest, or even retard the progression of the pathogenesis. Recent findings indicate the autophagy‐lysosome systems as appealing targets for pharmacological intervention. Autophagy exerts a critical role in controlling neuronal protein homeostasis, which is perturbed in HD, and is compromised in the pathogenesis of several neurodegenerative diseases. Type 2 transglutaminase (TG2) plays an important role both in apoptosis and autophagy regulation, and accumulates at high levels in cells under stressful conditions. TG2 inhibition, achieved either via drug treatments or genetic approaches, has been shown to be beneficial for the treatment of HD in animal models. In this review we will discuss the relevance of TG2 to the pathogenesis of HD, in an effort to define novel therapeutic avenues.Keywords
This publication has 128 references indexed in Scilit:
- Autophagy and the degradation of mitochondriaMitochondrion, 2010
- Opposing Effects of Two Tissue Transglutaminase Protein Isoforms in Neuroblastoma Cell DifferentiationJournal of Biological Chemistry, 2010
- Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP diseaseJournal of Cell Biology, 2009
- Role of mitochondrial dysfunction in the pathogenesis of Huntington's diseaseBrain Research Bulletin, 2009
- Huntingtin as an essential integrator of intracellular vesicular traffickingTrends in Cell Biology, 2009
- Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanismNature Structural & Molecular Biology, 2009
- Autophagy in neurodegeneration and developmentBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008
- Impaired Protein Aggregate Handling and Clearance Underlie the Pathogenesis of p97/VCP-associated DiseaseJournal of Biological Chemistry, 2008
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- Two isoforms of tissue transglutaminase mediate opposing cellular fatesProceedings of the National Academy of Sciences, 2006